At this point, we do not exclude the possibility that following peripheral administration some of the injected CXCL10-Ig or CXCL9-Ig would enter the tumor site, and therefore may have an additional contribution to CXCR3+ cell recruitment to the TEM [208,209]. The gene discussed is CXCR3; the disease is neoplasm.